Sequence Sciences is San Diego’s leading bio-storage provider for the biopharma and medical device industries. We provide unparalleled customer service and ultra-rapid turnaround across multiple temperatures and under GMP-compliant QMS monitoring.We also offer study design, assay development, and validation across sequencing (DNA/RNA and long-read sequencing including methylation), Mass-Spectrometry/Liquid chromatography, PCR and ELISA, as well as sourcing of clinical/remnant samples.https://sequencesciences.com/

Business development consulting as well as freelance medical writing & editing, especially for non-native English speakers and US market entry. Journal manuscripts, regulatory writing (IND, NDA, IB), etc. Grant-writing (multiple funded SBIR grants).

Neuroservices-Alliance provides services from complementary CNS platforms: in vitro & in vivo electrophysiology and behavioral tests. Our integrated functional data from rodent and human tissues accelerate CNS and pain research programs thanks to fast and robust lead selection & optimization, investigation of MOA, and validation of target engagement.Labs in San Diego, CA, and France provide access to expertise in functional cell-based assays, e.g., electrophysiology/MEA/Ca2+ imaging, as well as in vivo behavioral/slice ephys/optogenetics. We cover in vivo (pain, behavioral and ephys) as well as in vitro work (iPSC-derived and primary neurons, as well as disease models for pharmacology/compound profiling).

Sapient applies an end-to-end biomarker discovery platform to provide a deeper understanding of human biology and effectively align biological targets, patients, and drug therapies. Sapient’s three-pronged platform leverages advanced mass spectrometry technologies, computational learning, and a proprietary longitudinal Human Biology Database to enable population-level discovery of biomarkers, and derive actionable insights to optimize and expedite drug development. We can then answer the 'so what?' questions in drug discovery and development and clinical trials.

Our core expertise is combining physiologically-relevant 2D and 3D cell models and quantitative fluorescence imaging to answer research questions in CNS, immunology, (immuno)oncology, NASH, mitochondrial health, etc. We also partner with innovative platform companies to offer unique services and capabilities to clients.• Develop global business plan for phenotypic drug screening services using high-content imaging • Partnership development with platform/cell technology companies, experience in multiple therapeutic areas (neuroscience, (immuno)oncology, rare disease, etc.)

BioSeek/DiscoveRx/Eurofins progressed via acquisitions. Responsible for global business initiatives within the phenotypic platforms and medicinal chemistry offerings of Eurofins Pharma Discovery Services.

Global responsibility for revenue goals in the BioSeek Division. BioSeek has developed primary human cell-based assay systems capable of testing compounds and biologics on a variety of cell types. We combine this profiling with BioSeek’s compound database to rapidly select and prioritize compounds in development, either via target-based efficacy or toxicity criteria. We can also measure individual patient responses, perform biomarker validation, and de-convolute mechanism of action for targets of interest. (Senior Director, May 2012-Nov 2016; now Eurofins DiscoverX position above)

GenScript has created a one-stop, customizable service package that incorporates custom gene synthesis & cloning, peptide synthesis, protein production & purification, monoclonal & polyclonal antibody production, assay development, structural biology, and in vivo work. Our unified model and dedication to excellence makes us the ideal partner for any early-stage drug discovery project. GenScript provides direct support by acting as the client’s R&D bio-reagent and bio-assay center.GenScript continues pursuing better ways of meeting customers' challenging needs for quality services and technological innovation. I manage a territory that covers the Western US, Japan, Australia, Singapore India, and Korea.

Completed a 12-week Repurposing Business Training program and volunteered two weeks to coach a business in refining its purpose and developing an end-to-end plan to make a positive impact on society.

• Advise CEO (direct report) on all worldwide business development and licensing activities, including creating and implementing a global business plan and business strategies for both Biocortech’s lead therapeutic compounds and proprietary assay system for CNS indications• Draft term sheets and license agreements; perform financial modeling; pursue M&A opportunities; establish negotiation strategy; and manage current collaborative R&D agreements • Interact with existing corporate contacts to facilitate communication, track milestones, and identify scope for enhancing these relationships, including preparing and giving presentations.• Collect data and perform multiple business analyses for corporate/project strategies, including business feasibility studies, net product valuation, and business plan

Acucela is focused on developing drugs for eye disease. My primary role is business development--looking to identify pharma/biotech partners for our screening technology and lead clinical compounds.

• Facilitated cross-functional, team-based decision making and drug discovery project management for a nerve regeneration drug discovery project (FK1706) that reached Phase 2 trials• Managed KOL input into trial design, NPV and TPP assessments for product indications• Managed multiple global collaborations to meet or exceed project deadlines

NSF Summer Research Institute in Japan

Department of Pharmacology, Vanderbilt University, Nashville, TNDistribution of 5HT2C receptors in Rat Brain.

Department of Environmental Microbiology, Pacific Northwest National Laboratories, Richland, WAEnvironmental Microbiology.

Department of Zoology, University of Washington, Seattle, WAOrganization of the stomatogastric neuropil of the crab, Cancer borealis.